Opinion|Videos|June 27, 2024

Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

  1. What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
  2. What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options? 

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo